Advertisement
Table 1 Incidence rate and excess risk attributable to statins for myopathy, hepatic disorder and diabetes
| Author, year | Incidence/10.000 person-years or % (95% CI) | Excess risk/10.000 person-years or % | Exposure definition | Outcome definition |
|---|---|---|---|---|
| Myopathy | ||||
| Gaist et al.[50] | 2.30 | 2.10 | One prescription and additional 30 days supply | Medical codes for myopathic events and validation by independent blind review of medical records |
| (1.20 to 4.40) | ||||
| Hippisley-Cox et al.[55] | 0.26% | 0.22% | First prescription after January 2002 | Medical codes for moderate or serious myopathic events (myopathy or rhabdomyolysis or a CK ≥4X ULN) |
| (0.24% to 0.28%) | ||||
| McClure et al.[77] | 9.06 | 5.77 | One prescription during the study period | Medical codes for myopathy and CK ≥10X ULN |
| (n.r.) | ||||
| Smeeth et al.[94] | 0.11% | 0.08% | First prescription after January 1995 | Medical codes for myositis or myolysis |
| (n.r.) | ||||
| Hepatic disorder | ||||
| Hippisley-Cox et al.[55] | 1.20% | 0.50% | First prescription after January 2002 | ALT ≥120 IU/l among patients without chronic liver disease |
| (1.13% to 1.22%) | ||||
| Smeeth et al.[94] | 1.60% | 0.30% | First prescription after January 1995 | Medical codes for acute liver disease |
| First year only | 0.44% | 0.16% | ||
| (n.r.) | ||||
| Diabetes | ||||
| Culver et al.[41] | 6.25% | 2.25% | One prescription at the first screening interview and three-year follow-up | Self-report of a new physician diagnosis of treated diabetes |
| (5.71% to 6.84%) | ||||
| Jick et al.[59] | n.a. | n.a. | Two prescriptions one year before index date | Medical code for first diagnosis of diabetes plus more than two prescriptions for a hypoglycaemic agent or three records of diet management |
